abatacept
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: T-lymphocyte activation antigen CD80.
- Target
- T-lymphocyte activation antigen CD80
- Mechanism
- T-lymphocyte activation antigen CD80 inhibitor
pharma · Acute myeloid leukemia · Juvenile idiopathic arthritis
Istituto Gentili Italia
Istituto Gentili S.r.l.
Istituto Gentili Italia drug portfolio — 114 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Via San Giuseppe Cottolengo, 15, Milano, Lombardia 20143, IT HQ
1917 Founded
121 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Via San Giuseppe Cottolengo, 15, Milano, Lombardia 20143, IT
- Founded
- 1917
- Employees
- 121
- Programs
- 50
- Drugs
- 114
- Patents
- 0
Istituto Gentili Italia pipeline
Portfolio lens on 114 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Istituto Gentili Italia drug portfolio — 114 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
adalimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
US regulatory status: approved. Molecular target: Interleukin-2 receptor.
- Target
- Interleukin-2 receptor
- Mechanism
- Interleukin-2 receptor agonist
-
allogeneic t cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δlngfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2)
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Istituto Gentili Italia's portfolio. Mechanism: Somatic cell supplemental therapy.
- Mechanism
- Somatic cell supplemental therapy
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
atezolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
azacitidine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 3A inhibitor
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
canakinumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-1 beta.
- Target
- Interleukin-1 beta
- Mechanism
- Interleukin-1 beta inhibitor
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
cladribine
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-2.
- Target
- Adrenergic receptor alpha-2
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
clopidogrel
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in Istituto Gentili Italia's portfolio. Mechanism: Purinergic receptor P2Y12 antagonist.
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
cytarabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
daunorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Istituto Gentili Italia's portfolio. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
decitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 1 inhibitor
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
durvalumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
edotreotide
Various (V09)Various (V09) compound in Istituto Gentili Italia's portfolio.
-
elacestrant
Antineoplastic and immunomodulating agents (L02)Antineoplastic and immunomodulating agents (L02) compound in Istituto Gentili Italia's portfolio. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha degrader
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
etanercept
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
US regulatory status: approved. Molecular target: DNA topoisomerase II.
- Target
- DNA topoisomerase II
- Mechanism
- DNA topoisomerase II inhibitor
-
US regulatory status: approved. Molecular target: Aromatase.
- Target
- Aromatase
- Mechanism
- Cytochrome P450 19A1 inhibitor
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA polymerase (alpha/delta/epsilon).
- Target
- DNA polymerase (alpha/delta/epsilon)
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor alpha.
- Target
- Peroxisome proliferator-activated receptor alpha
- Mechanism
- Peroxisome proliferator-activated receptor alpha agonist
-
gemtuzumab ozogamicin
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Myeloid cell surface antigen CD33 binding agent
-
gilteritinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Istituto Gentili Italia's portfolio. Molecular target: Receptor-type tyrosine-protein kinase FLT3.
- Target
- Receptor-type tyrosine-protein kinase FLT3
- Mechanism
- Tyrosine-protein kinase receptor FLT3 inhibitor
-
glasdegib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Istituto Gentili Italia's portfolio. Molecular target: Protein smoothened.
- Target
- Protein smoothened
- Mechanism
- Smoothened homolog antagonist
-
golimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.
- Target
- Solute carrier family 12 member 3
- Mechanism
- Thiazide-sensitive sodium-chloride cotransporter inhibitor
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
infliximab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
ivacaftor
Respiratory system (R07)US regulatory status: approved. Molecular target: Cystic fibrosis transmembrane conductance regulator.
- Target
- Cystic fibrosis transmembrane conductance regulator
- Mechanism
- Cystic fibrosis transmembrane conductance regulator positive modulator
-
ivosidenib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Isocitrate dehydrogenase [NADP] cytoplasmic.
- Target
- Isocitrate dehydrogenase [NADP] cytoplasmic
- Mechanism
- Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Acetylcholinesterase.
- Target
- Acetylcholinesterase
- Mechanism
- Acetylcholinesterase inhibitor
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records. Mechanism: Mitochondrial complex I (NADH dehydrogenase) inhibitor.
- Mechanism
- Mitochondrial complex I (NADH dehydrogenase) inhibitor
-
methotrexate
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Dihydrofolate reductase inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
obinutuzumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
octreotide
Systemic hormonal preparations (H01)Systemic hormonal preparations (H01) compound in Istituto Gentili Italia's portfolio. Mechanism: Somatostatin receptor agonist.
- Mechanism
- Somatostatin receptor agonist
-
olaparib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: PARP 1, 2 and 3.
- Target
- PARP 1, 2 and 3
- Mechanism
- PARP 1, 2 and 3 inhibitor
-
US regulatory status: approved. Mechanism: Essential for cellular homeostasis.
- Mechanism
- Essential for cellular homeostasis
-
patiromer
Various (V03)Various (V03) compound in Istituto Gentili Italia's portfolio. Molecular target: Potassium.
- Target
- Potassium
- Mechanism
- Potassium chelating agent
-
US regulatory status: approved. Molecular target: Potassium.
- Target
- Potassium
- Mechanism
- Potassium chelating agent
-
pegfilgrastim
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.
- Target
- Granulocyte colony-stimulating factor receptor
- Mechanism
- Granulocyte colony stimulating factor receptor agonist
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
perampanel
Nervous system (N03)US regulatory status: approved. Molecular target: Glutamate receptor ionotropic AMPA.
- Target
- Glutamate receptor ionotropic AMPA
- Mechanism
- Glutamate receptor ionotropic AMPA antagonist
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
prasterone
Genito-urinary system and sex hormones (G03)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
radium ra223 dichloride
Various (V10)Various (V10) compound in Istituto Gentili Italia's portfolio. Mechanism: Radiotherapy agent.
- Mechanism
- Radiotherapy agent
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
regorafenib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Discoidin domain-containing receptor 2.
- Target
- Discoidin domain-containing receptor 2
- Mechanism
- Fibroblast growth factor receptor 2 inhibitor
-
rituximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
US regulatory status: approved. Molecular target: Muscle-type nicotinic acetylcholine receptor.
- Target
- Muscle-type nicotinic acetylcholine receptor
- Mechanism
- Muscle-type nicotinic acetylcholine receptor antagonist
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
secukinumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-17A.
- Target
- Interleukin-17A
- Mechanism
- Interleukin 17A inhibitor
-
US regulatory status: approved. Mechanism: Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor.
- Mechanism
- Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor
-
semaglutide
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.
- Target
- Glucagon-like peptide 1 receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
sugammadex
Various (V03)US regulatory status: approved.
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
temozolomide
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
thiotepa
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
trifluridine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records.
-
venetoclax
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Apoptosis regulator Bcl-2.
- Target
- Apoptosis regulator Bcl-2
- Mechanism
- Apoptosis regulator Bcl-2 inhibitor
-
Development asset linked to Istituto Gentili Italia in public FDA and regional records. Mechanism: Tubulin inhibitor.
- Mechanism
- Tubulin inhibitor